Fresenius SE & Co. KGaA (FSNUY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fresenius SE & Co. KGaA (FSNUY) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0.
Ultimo analisis: 16 mar 2026Fresenius SE & Co. KGaA (FSNUY) Resumen de Asistencia Médica y Tuberías
Fresenius SE & Co. KGaA, a German-based healthcare conglomerate with a market cap of $120.94 billion, delivers dialysis products, hospital management, and outpatient care services globally. Operating through four key segments, Fresenius competes with diversified healthcare providers while maintaining a focus on integrated healthcare solutions and a dividend yield of 2.14%.
Tesis de Inversión
Fresenius presents a compelling investment case based on its diversified healthcare portfolio and global footprint. The company's established position in the dialysis market, through Fresenius Medical Care, provides a stable revenue stream. Growth catalysts include the expansion of Fresenius Kabi's biosimilars business and the increasing demand for healthcare services in aging populations. With a P/E ratio of 23.07 and a profit margin of 5.1%, Fresenius demonstrates profitability. However, investors may want to evaluate potential risks such as regulatory changes and competition within the healthcare industry. The company's beta of 0.91 suggests lower volatility compared to the broader market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $120.94 billion, reflecting its significant presence in the healthcare sector.
- P/E ratio of 23.07, indicating investor valuation relative to earnings.
- Profit margin of 5.1%, demonstrating the company's ability to generate profit from revenue.
- Gross margin of 25.0%, showcasing the efficiency of production and service delivery.
- Dividend yield of 2.14%, offering a return to investors through dividend payments.
Competidores y Pares
Fortalezas
- Diversified business model across healthcare segments.
- Global presence with operations in multiple countries.
- Established market position in dialysis services.
- Strong brand reputation and customer relationships.
Debilidades
- Exposure to regulatory risks and pricing pressures in the healthcare industry.
- Dependence on reimbursement policies and healthcare reforms.
- Potential for product liability claims and litigation.
- Complexity of managing a large and diverse organization.
Catalizadores
- Ongoing: Expansion of Fresenius Kabi's biosimilars portfolio, addressing autoimmune and oncology diseases, expected to drive revenue growth.
- Ongoing: Increasing demand for dialysis services due to the rising prevalence of chronic kidney disease.
- Upcoming: Potential acquisitions to expand Fresenius's product portfolio and geographic reach by the end of 2026.
- Ongoing: Investments in technological innovation, such as AI and telemedicine, to improve efficiency and patient outcomes.
- Ongoing: Growth in emerging markets, where healthcare infrastructure is developing and demand for medical services is increasing.
Riesgos
- Ongoing: Regulatory risks and pricing pressures in the healthcare industry could impact profitability.
- Potential: Changes in government regulations and healthcare policies may affect reimbursement rates and market access.
- Potential: Product liability claims and litigation could result in financial losses and reputational damage.
- Ongoing: Competition from other healthcare providers and pharmaceutical companies may erode market share.
- Potential: Economic downturns and healthcare spending cuts could reduce demand for Fresenius's products and services.
Oportunidades de crecimiento
- Expansion of Biosimilars Portfolio: Fresenius Kabi's biosimilars business represents a significant growth opportunity. As patents for branded biologics expire, the demand for biosimilars is expected to increase. Fresenius can leverage its manufacturing capabilities and distribution network to capture a larger share of this market. The global biosimilars market is projected to reach $100 billion by 2029, offering substantial revenue potential for Fresenius.
- Growth in Emerging Markets: Fresenius can expand its presence in emerging markets, where healthcare infrastructure is developing and the demand for medical services is increasing. By establishing partnerships and investing in local facilities, Fresenius can tap into these high-growth markets. Emerging markets are expected to drive a significant portion of the growth in the healthcare industry over the next decade.
- Increasing Demand for Dialysis Services: The prevalence of chronic kidney disease is rising globally, driving demand for dialysis services. Fresenius Medical Care, as a leading provider of dialysis products and services, is well-positioned to benefit from this trend. The global dialysis market is projected to grow at a steady pace, providing a stable revenue stream for Fresenius.
- Strategic Acquisitions: Fresenius can pursue strategic acquisitions to expand its product portfolio, geographic reach, and market share. By acquiring complementary businesses, Fresenius can strengthen its competitive position and accelerate growth. The company has a track record of successful acquisitions, and it can continue to leverage this strategy to create value for shareholders.
- Technological Innovation: Fresenius can invest in technological innovation to improve its products and services, enhance efficiency, and reduce costs. By adopting new technologies such as artificial intelligence and telemedicine, Fresenius can gain a competitive edge and improve patient outcomes. The healthcare industry is undergoing a digital transformation, and Fresenius can capitalize on this trend.
Oportunidades
- Expansion in emerging markets with growing healthcare demand.
- Growth in biosimilars market as patents for branded biologics expire.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Technological innovation to improve products and services.
Amenazas
- Competition from other healthcare providers and pharmaceutical companies.
- Economic downturns and healthcare spending cuts.
- Changes in government regulations and healthcare policies.
- Disruptive technologies and new market entrants.
Ventajas competitivas
- Established market position in dialysis services through Fresenius Medical Care.
- Diversified business model spanning dialysis, hospital management, and pharmaceutical products.
- Global presence with operations in multiple countries.
- Strong brand reputation and customer relationships.
- Extensive distribution network for medical products.
Acerca de FSNUY
Founded in 1912 and headquartered in Bad Homburg vor der Höhe, Germany, Fresenius SE & Co. KGaA has evolved into a global healthcare leader. Initially focused on supplying pharmaceutical products, the company expanded into dialysis services in the 1960s, marking a pivotal shift. Today, Fresenius operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care provides dialysis products and services for patients with chronic kidney failure. Fresenius Kabi offers IV drugs, clinical nutrition, and medical devices. Fresenius Helios operates hospitals and outpatient clinics, primarily in Germany and Spain, offering a range of medical services, including fertility treatments. Fresenius Vamed manages projects and provides services for hospitals and other healthcare facilities, including project development, planning, and construction. With a global presence and a focus on integrated healthcare solutions, Fresenius serves a diverse range of patients and healthcare providers.
Qué hacen
- Provides products and services for dialysis patients.
- Operates hospitals and outpatient clinics.
- Offers IV drugs, clinical nutrition, and medical devices.
- Manages projects for hospitals and healthcare facilities.
- Provides project development and construction services.
- Offers maintenance and technical management services.
- Provides fertility treatments through clinics in multiple countries.
Modelo de Negocio
- Provides dialysis products and services to patients with chronic kidney failure.
- Operates hospitals and outpatient clinics, generating revenue from patient care services.
- Develops, manufactures, and sells IV drugs, clinical nutrition products, and medical devices.
- Provides project management and construction services for healthcare facilities.
- Offers maintenance and operational management services for hospitals and clinics.
Contexto de la Industria
Fresenius operates in the healthcare industry, which is characterized by increasing demand driven by aging populations and advancements in medical technology. The company competes with other healthcare providers and pharmaceutical companies in a fragmented market. The industry is subject to regulatory scrutiny and pricing pressures. Fresenius's diversified business model, spanning dialysis, hospital management, and pharmaceutical products, positions it to capitalize on various growth opportunities within the healthcare sector. The global healthcare market is projected to continue expanding, driven by chronic diseases and the need for advanced medical treatments.
Clientes Clave
- Patients with chronic kidney failure requiring dialysis services.
- Hospitals and healthcare providers seeking medical products and services.
- Patients seeking treatment at Fresenius Helios hospitals and clinics.
- Healthcare facilities requiring project management and construction services.
- Patients seeking fertility treatments.
Finanzas
Gráfico e información
Precio de la acción de Fresenius SE & Co. KGaA (FSNUY): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para FSNUY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para FSNUY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de FSNUY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Michael Sen
CEO
Michael Sen is the CEO of Fresenius SE & Co. KGaA, a global healthcare company. He has a strong background in the healthcare industry, with experience in pharmaceuticals, medical devices, and healthcare services. Before joining Fresenius, he held leadership positions at major healthcare companies, including Siemens Healthineers. His expertise includes strategic planning, business development, and operational management. Sen is known for his focus on innovation and growth.
Historial: Under Michael Sen's leadership, Fresenius has focused on streamlining operations and enhancing its core businesses. He has emphasized innovation and digital transformation to improve patient outcomes and drive efficiency. Key initiatives include expanding the biosimilars portfolio and strengthening the company's presence in emerging markets. Sen's strategic decisions have aimed to position Fresenius for long-term growth and success.
Información de ADR de Fresenius SE & Co. KGaA No patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. FSNUY is a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the strict listing requirements of major exchanges. This allows U.S. investors to invest in Fresenius while the actual shares are held by a depositary bank.
- Ticker del mercado local: Frankfurt Stock Exchange (FSNU), Germany
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: FSNU
Información del mercado OTC de FSNUY
The OTC Other tier represents the lowest tier of the OTC market, indicating that Fresenius SE & Co. KGaA (FSNUY) has chosen not to meet the requirements for the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial disclosure and do not have to adhere to minimum financial standards. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and regulatory oversight.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Lower liquidity and wider bid-ask spreads.
- Potential for fraud and manipulation.
- Higher volatility compared to stocks listed on major exchanges.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Obtain and review available financial statements and disclosures.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Evaluate the company's business model and growth prospects.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making an investment decision.
- Established operating history as Fresenius SE & Co. KGaA.
- Presence in the healthcare industry with recognizable brands.
- Global operations and customer base.
- Existing ADR structure, even if Level 1.
- Availability of some financial information, even if limited.
Acciones de Fresenius SE & Co. KGaA: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar FSNUY?
Evaluar FSNUY implica revisar los fundamentales, el consenso de analistas y los factores de riesgo. Fortaleza clave: Diversified business model across healthcare segments.. Riesgo principal a monitorear: Ongoing: Regulatory risks and pricing pressures in the healthcare industry could impact profitability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de FSNUY?
El MoonshotScore califica a FSNUY de 0 a 100 en salud financiera, impulso del mercado y factores de riesgo. Puntuaciones superiores a 70 indican calificaciones más altas, 50-70 moderadas y por debajo de 50 calificaciones más bajas. Se recalcula diariamente. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de FSNUY?
Los precios de FSNUY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre FSNUY?
La cobertura de analistas para FSNUY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en FSNUY?
Las categorías de riesgo para FSNUY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Regulatory risks and pricing pressures in the healthcare industry could impact profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de FSNUY?
La relación P/E para FSNUY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está FSNUY sobrevalorada o infravalorada?
Determinar si Fresenius SE & Co. KGaA (FSNUY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de FSNUY?
Fresenius SE & Co. KGaA (FSNUY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on the most recent available information.
- Market projections are subject to change based on economic and industry conditions.
- This analysis is for informational purposes only and does not constitute investment advice.